medical writing services
An industry leader in providing global, strategic, responsive, and flexible medical writing project support.

Medical Writing Services
ProPharma provides comprehensive medical writing and document management services for all clinical and safety documentation required throughout the drug development lifecycle as well as other scientific communications.
Core strengths include the experience of our team and the ability of our talented medical writers to distill and assimilate scientific data to produce clear, concise, credible, and complete deliverables.

ProPharma medical writers:
- Autonomously drive the document development process
- Make early contact with the team, identify key stakeholders, and establish clear expectations
- Work with the team to develop timelines, determine project drivers, and assess all potential risks early in the process
- Lead document development, develop and refine key messages, and coordinate and manage input from cross-functional stakeholders
- Manage client review cycles, comment adjudication, and quality review
- Facilitate signoff, publishing, and distribution of final, approved documents
Benefits of Working with Our Medical Writing & Editing Team

GLOBAL AND EXPERIENCED
Our medical writers are located across North America, UK, EU, Australia, China, Japan, and India. Our writers have an average of 8 years of writing experience, many have advanced degrees, and the depth of experience encompasses multiple therapy areas.

SCALABLE
With access to a large pool of experienced medical writing resources, we can scale up as needed to accommodate any demand.

QUALITY FOCUSED
We believe quality is intentional. Using a documented and systematic approach, we build quality into each document as it evolves through its lifecycle.

ADEPT PROJECT AND STAKEHOLDER MANAGEMENT
With experience managing deliverables from start to finish, we autonomously coordinate all aspects of input, production, and review of every document while skillfully collaborating with global, cross-functional teams.
Our Medical Writing Portfolio
Our medical writing portfolio encompasses execution of hundreds of deliverables spanning all types of clinical, safety, and other scientific communication documents, including but not limited to:
Clinical
- Clinical Study Reports (CSRs)
- Protocols and Protocol Amendments
- Investigator’s Brochures (IBs) and IB Updates
- Regulatory Submission Summary Documents (IND/NDA/MAA/CTA)
- Responses to Questions (RTQs)/Regulatory Responses (across multiple health authorities)
- Pre-Meeting Packages/Briefing Packages
- Orphan Drug Applications
- Pediatric Investigation Plans
- Pediatric Study Plans (including waivers)
- Health Outcomes Economics/Real World Evidence Documents
- Fast Track Designation
- Orphan Drug Designation (ODD) Application/Annual Reports
- Immunogenicity Reports
- Ethnic Sensitivity Reports
- Conditional Marketing Authorization (CMA)


Safety
- Development Safety Update Reports (DSURs)
- Periodic Benefit Risk and Evaluation Reports (PBRERs)
- Periodic Safety Update Reports (PSURs)
- Periodic Adverse Drug Experience Reports (PADERs)
- Risk Management Plans
- Assessment of Benefit Risk (ABR)
- Annual Reports
- Patient Safety Narratives
Nonclinical
- Pharmacology, Pharmacokinetic, and Toxicology Reports (in vivo/in vitro)
- Bioanalytical Reports
Diagnostics
- Protocol Proposals
- Clinical Validation Plan/Clinical Performance Plan
- Clinical Validation Report/Clinical Performance Report
- Clinical Study Protocols (CSPs)
- Clinical Study Reports (CSRs)
- Intended Use Statements
- Performance Evaluation Plan (PEP)
- Performance Evaluation Report (PER)
- State-of-the-Art Determination (SOTA)
- Scientific Validity Report (SVR)
- Medical Assessment
- Medical Opinion Documents


Devices
- Clinical Evaluation Plans (CEPs)
- Clinical Evaluation Reports (CERs)
- Investigational Device Exemption (IDE)
Publications
- Scientific Manuscripts/Abstracts
- Posters
- Literature Reviews/Summaries
- Oral Presentations
Other Scientific Documents
- Plain Language Documents (protocol synopses, results summaries)
- Informed Consent Forms (ICFs)
- Regulatory White Papers
- Consumer Health Product Documents
Medical Writing Services Frequently Asked Questions
Click on frequently asked questions about ProPharma's medical writing services and experience.
We provide medical writing services to pharmaceutical/biotech companies of all sizes (including small, mid-size, and big pharma).
The ProPharma medical writing process is an "author-driven" process that can be modified and customized to meet specific client needs. Our overall goals for each deliverable are to meet timelines, manage challenges, produce a high-quality document, and minimize cost.
At kickoff, the medical writer helps to develop the document timelines, establish team expectations and document strategy, identify potential risks, and establish a risk management plan if needed. During document development, the medical writer collects study documents, collaborates with the authoring team on document content and quality, and follows the communication plan.
The medical writer manages the document review cycles, including comment incorporation and adjudication in collaboration with the authoring team, ensures timeline integrity, and facilitates quality control (QC) reviews, final document approval, and electronic publishing, as necessary.
Yes, ProPharma medical writers collaborate closely with global cross-functional teams during all stages of document development, engaging at a level that meets each individual client’s needs.
In addition to content development, ProPharma writers are also trained to support publications strategy and project management. Our writers will drive timelines, manage meetings, and coordinate with both internal sponsor partners and external KOLs. They can assist your team with everything from researching target journals to creating graphics. They will proactively review Rules for Authors to ensure adherence to the guidelines and can also manage the journal submission. Our team is flexible in providing whatever services you need to support your publications.
ProPharma recruits and retains experienced medical writers, with routine training on our internal policies, SOPs, and work practice documents. Training on client-specific processes is provided as needed. Medical writing leadership mentors the medical writing staff to ensure consistency in performance, communication, and project/time management. Senior/peer reviews of documents provide continuous learning opportunities for writers to ensure quality and internal consistency of our work product. We designate document-specific SMEs who are available to answer questions about process, timelines, documentation, and best practices. We work together to answer questions internally to provide learning opportunities and minimize any interruption or burden on our clients.
ProPharma has also developed an extensive early talent and training program that provides hands-on, mentor-driven medical writing training and support for those interested in becoming medical writers. The foundational training program provides core knowledge and soft skills training (e.g., stakeholder management, communication, teamwork/collaboration, time/project management) through document-specific curriculum, hands-on exercises, shadowing, and direct mentoring designed to accelerate the learning curve and train the next generation of medical writers.
Have additional medical writing questions?
We'd be happy to talk with you
about your unique needs and goals.
News & Insights

September 27, 2023
The Impact of a US Government Shutdown on the Food and Drug Administration
U.S. lawmakers are actively attempting to negotiate a deal to prevent a government shutdown on October 1, 2023. Along with many other government agencies, the ability of the Food and Drug...

September 25, 2023
DSCSA Requirements and Responsibilities for Drug Manufacturers (Sponsor vs CMO)
With the final deadline for complete compliance with the FDA's Drug Supply Chain Security Act (DSCSA) looming on the horizon, where do you find your organization? Although the FDA has now issued two...

September 27, 2023
ProPharma Appoints Alena Hammond as Global Head of Clinical Operations
Raleigh, NC, September 27, 2023: ProPharma Group (ProPharma), the leading global provider of regulatory, clinical and compliance services for the life sciences industry, and a portfolio company of...

September 13, 2023
ProPharma Introduces ClinCHAT, a Solution to Unleash the Power of Real-World Evidence with Conversational AI
Raleigh, NC, September 13, 2023: ProPharma Group (ProPharma), the leading global provider of regulatory, clinical and compliance services for the life sciences industry, and a portfolio company of...

August 30, 2023
ProPharma Expands Regulatory Sciences Team in the Japan and Asia-Pacific Region with Addition of Neama Baho
RALEIGH, NC, August 30, 2023: ProPharma Group (ProPharma), the leading global provider of regulatory, clinical and compliance services for the life sciences industry, and a portfolio company of...

May 3, 2022
ProPharma Group Named Top 10 CRO 2022 by Pharma Tech Outlook
ProPharma Group Named Top 10 CRO 2022 by Pharma Tech Outlook A Customer-Centric Approach to Clinical Research Solutions ProPharma Group is honored to be named Top 10 CRO 2022 by Pharma Tech Outlook...

April 21, 2022
ProPharma Group Named Best Pharmaceutical Regulatory & Compliance Consultancy: 2022 Corporate Excellence Awards
ProPharma Group Named Best Pharmaceutical Regulatory & Compliance Consultancy: 2022 Corporate Excellence Awards: ProPharma Group is honored to be awarded “Best Pharmaceutical Regulatory & Compliance...

June 10, 2022
The Cost of Poor Project Management
Project Management isn’t for the faint of heart. There is a shockingly high rate of project failure… but on the other hand, great project management can be a key differentiator that leads a company...

August 31, 2022
Successfully Passing MHRA Inspections for Overseas Manufacturing Sites
ProPharma Group offers GMP and GDP compliance services from clinical development to commercial distribution of the products' lifecycle. ProPharma Group’s Compliance and Quality team completed the...
News & Insights

September 27, 2023
ProPharma Appoints Alena Hammond as Global Head of Clinical Operations
Raleigh, NC, September 27, 2023: ProPharma Group (ProPharma), the leading global provider of regulatory, clinical and compliance services for the life sciences industry, and a portfolio company of...

September 13, 2023
ProPharma Introduces ClinCHAT, a Solution to Unleash the Power of Real-World Evidence with Conversational AI
Raleigh, NC, September 13, 2023: ProPharma Group (ProPharma), the leading global provider of regulatory, clinical and compliance services for the life sciences industry, and a portfolio company of...

August 30, 2023
ProPharma Expands Regulatory Sciences Team in the Japan and Asia-Pacific Region with Addition of Neama Baho
RALEIGH, NC, August 30, 2023: ProPharma Group (ProPharma), the leading global provider of regulatory, clinical and compliance services for the life sciences industry, and a portfolio company of...

April 21, 2022
ProPharma Group Named Best Pharmaceutical Regulatory & Compliance Consultancy: 2022 Corporate Excellence Awards
ProPharma Group Named Best Pharmaceutical Regulatory & Compliance Consultancy: 2022 Corporate Excellence Awards: ProPharma Group is honored to be awarded “Best Pharmaceutical Regulatory & Compliance...

Sep 27, 2023 11:57:42 AM
The Impact of a US Government Shutdown on the Food and Drug Administration
U.S. lawmakers are actively attempting to negotiate a deal to prevent a government shutdown on October 1, 2023. Along with many other government agencies, the ability of the Food and Drug...

Sep 25, 2023 4:59:00 PM
DSCSA Requirements and Responsibilities for Drug Manufacturers (Sponsor vs CMO)
With the final deadline for complete compliance with the FDA's Drug Supply Chain Security Act (DSCSA) looming on the horizon, where do you find your organization? Although the FDA has now issued two...

October 14, 2021
Accelerate European Market Access with Compliant and Comprehensive MAA Submission
Preparedness for Marketing Authorization Application (MAA) approval ensures an efficient application process and follow-up. Placing a medicinal product in the European market requires a license for...

March 18, 2022
Outsourcing QA - Reduce Time and Expense While Meeting Critical Requirements
There is a tendency for VPCs to rely solely on the QC/QA units within their outsourced CMO to perform quality functions. However, the sponsor organization has the ultimate responsibility for product...

October 14, 2021
Dedicated Project Manager Directs Regulatory Activities Throughout European Economic Area
Learn how a single point of contact oversaw local regulatory affairs activities across all 31 countries of the EEA. You’re developing a drug, biologic, or medical device product. There are a lot of...

September 1, 2022
Webinar: AI-Powered MI Contact Centers: Key Considerations for a Scalable & Global Medical Information Capability
Today's Medical Information (MI) industry is being driven by evolving customer behavior requiring a more rapid, omnichannel, and digital response to customer needs. The expectation for higher...

October 14, 2021
Ensure Successful Acquisitions with Complete and Accurate Regulatory Due Diligence
Ensure you have as much information as possible to thoroughly evaluate the potential investment when acquiring a company or product. When considering the acquisition of a new company or product, it...

October 14, 2021
Ensure Successful Batch Release, Regulatory Compliance with Experienced Qualified Persons
Streamlining a CMO’s manufacturing process helped ensure GMP compliance for EU batch release and USA inspection readiness. A contract manufacturing organization (CMO) needs to have a reliable quality...

September 28, 2023
How a Two-Part NDA Regulatory Strategy Resulted in Submission Success
Developing a New Drug Application (NDA) for submission to the FDA is an extremely complex process and one that can present challenges to even the most seasoned professionals. From ensuring you have...

October 4, 2021
How to Minimize Overdue Deviations: A Multi-Site Process Improvement Approach
A global biopharmaceutical client with multiple sites operating under a Warning Letter from the U.S. Food and Drug Administration (FDA) needed significant cross-functional support to meet remediation...

October 14, 2021
Identify At-Risk Drug Products and Ensure Compliance Before Nitrosamines Deadline
Risk evaluation of products containing chemically synthesized APIs must be done to assess adherence to nitrosamine regulations. Marketing Authorization Holders (MAHs) must perform a risk evaluation...

October 4, 2021
Increased Visibility for Senior Management with Custom PMO Design, Implementation
Time. Regardless of company size and the number of products in your portfolio, time is one thing we could all use more of. However, the more projects you have in your portfolio, the more stretched...

October 14, 2021
Initiating Enrollment for Accelerated COVID-19 Treatment Studies in 6 Days
In May 2020, as the FDA released new guidelines to accelerate the development of novel COVID-19 therapeutics and vaccines, our Clinical Services experts were asked to provide independent Data Safety...

October 14, 2021
MICC Overflow Solution Was Successfully Deployed and Preserved Customer Satisfaction
A routine safety letter to healthcare professionals (HCPs) was misinterpreted by recipients, causing a “recall-like” crisis event for a multinational pharmaceutical client. When a routine safety...

September 28, 2023
Insider Talks - The Journey of ATMPs From the Discovery to Routine GMP Real Life
In the competitive and fast-moving Cell and Gene Therapy (CGT) field, developers face a range of scientific, technical, and regulatory challenges that can quickly become overwhelming and costly. In...

May 19, 2022
Insider Talks - Tips to Adapt to Today’s Auditing Environment, an Auditor’s Perspective
As businesses face the shared global challenges of adapting to new operating models triggered by the recent pandemic, regulated drug and device sponsors, marketing authorization holders, and...

March 25, 2022
Insider Talks - To Decentralize or Not to Decentralize … That is the Question
Having a decentralized approach is critical to ensuring continuity in the face of disaster, and important in meeting your overall enrollment goals while increasing patient diversity. Join us for our...

October 14, 2021
Secure Timely Product Launch by Ensuring GDP Compliance Across Europe
Our client was in the phase of submitting a Marketing Authorization Application (MAA) in the EU and needed to apply for a Wholesale Distribution Authorization (WDA). After application and approval of...

October 14, 2021
Transfer and Manage Clinical Data Provided by Multiple Third-Party Vendors
Managing and sharing large amounts of clinical data provided by a team of ten plus vendors is extremely challenging and requires meticulous attention to detail and expert-level project management to...

October 14, 2021
Understanding Clinical Trial Requirements for Medical Device Label Extensions
After you have developed an FDA-regulated product and obtained marketing approval, you may think your job is done. However, after all the time, effort, money, and so much more that goes into product...

September 28, 2023
What You Need to Know About Regulatory Programs for Expedited Approval
Differentiating between the FDA and EMA's expedited approval pathways can be tricky. Learn the similarities and differences between them to help determine the best option(s) for your product. The...

October 17, 2021
Outsourcing of Medical Information Content Creation: Experience of 100 Clients
The time and effort required to write, review, edit, approve, maintain, distribute, and update Medical Information (MI) documents while retaining an auditable record of the search strategy is a great...

October 4, 2021
Outsourcing Medical Information Services: When to Consider a Dedicated Resource
Outsourcing Medical Information (MI) services can be an effective solution for ensuring the provision of MI services to HCPs and consumers globally. The most cost-effective model for the provision of...

May 3, 2023
Improve Quality & Consistency by Leveraging AI for Trial Master File Classification
Improve Quality and Consistency by Leveraging AI for Trial Master File Classification The whitepaper "Improve Quality and Consistency by Leveraging AI for Trial Master File Classification" addresses...